Innovation

AMSbiopharma participates in various research and development projects, our own or in collaboration with other private or public entities at regional, national or international level, always aimed at offering new analytical solutions that favour scientific progress and the continuous improvement of processes in different sectors.

CDTI INNTERCONECTA STEP 2025 – NEUROAON

AMSbiopharma has been awarded funding by the CDTI INNTERCONECTA STEP 2025 programme for the project titled “ADVANCED ANTISENSE OLIGONUCLEOTIDE THERAPIES FOR NEUROMUSCULAR DISEASES”, NEUROAON (ITC-20251291).

The general objective of NEUROAON is to design and develop therapeutic AONs for untreated neuromuscular diseases through rational oligonucleotide design, targeted delivery, and preclinical validation. This project is subsidized by CDTI with FEDER funds 2021–2027.

This collaborative project is led by ARTHEx Biotech, with the participation of AMS Biopharma Laboratory S.L., Polypeptide Therapeutic Solutions S.L., and ProtoQsar 2000 S.L.

FOEXGA Program – Bio Europe Event (Lisbon)

This entity was beneficiary of the FOEXGA Program.
The main objective of this aid is to encourage the implementation of foreign promotion actions that generate competitive advantages. The intended result is the promotion of SMEs and their products and services, increasing the number of export-based companies.

LYCTUS – Development of protein degraders in neurological diseases

              

Objective: To develop an innovative therapy against ischemic stroke (ACS) and complications derived from reperfusion techniques, such as hemorrhagic transformation (HT), through the use of targeted protein degraders. These degraders, mAb-LYTACs, are heterobifunctional molecules composed of a highly specific monoclonal antibody (MAb) against a protein of interest and an internalizing peptide that target said extracellular proteins to lysosomal degradation.

Pursued results: complete the preclinical development of these compounds by evaluating, in vitro and in vivo, their Mechanism of Action (MoA), biodistribution, safety and efficacy.

Beneficiary company, group leader: Aptadegrad, S.L.

Other beneficiaries: AMS Biopharma Laboratory, S.L., Fundación Pública Galega Instituto de Investigación Sanitaria de Santiago de Compostela FIDIS, Diversa Technologies, S.L.

Dates: 15/05/2024 – 15/12/2027

IN856C 2024/08

Galicia Exports Companies

   

This entity was a beneficiary of grants for implementing international promotion activities for Galician companies.

The main objective of these grants is to incentivize international promotion activities that generate competitive advantages. The intended result is to boost SMEs and their products and services, increasing the number of companies in the export base.

IG622A-2025-000-000210

SmarTZ4Milk – Smart, Traceable, Sustainable, and Connected Dairy Value Chain

Primary Project Title: Research on Proteomics-Based Analytical Methods for the Study of Milk Proteins

“SmarTZ4Milk – Smart, Traceable, Sustainable, and Connected Dairy Value Chain” is a flagship project led by the Galicia Food Cluster (Clusaga) through the Next Generation Galicia Food Technical Office. Its primary goal is to transform the Galician dairy sector and enhance its competitiveness through R&D&I and investment in sustainability.

This project has been funded through grants for integration and transformation initiatives in the industrial value chain of the agri-food sector, as part of the Strategic Project for Economic Recovery and Transformation in Agri-Food (PERTE AGRO). It falls within the framework of the Recovery, Transformation, and Resilience Plan, financed by the European Union and managed by the Ministry of Industry, Trade, and Tourism.

Aid for investment projects, co-financed by the European Union

The main objective of this aid is the reinforcement of sustainable growth and competitiveness of SMEs and the creation of employment in these, also through productive investments.
The intended result is the creation of new business projects, as well as the expansion, modernization and diversification of pre-existing business initiatives, favoring sustainability, competitiveness and the creation and maintenance of employment.

AMSbiopharma Innovation Plan

“To systematize and strengthen innovation by implementing activities integrated into process and organizational innovation plans.”

This operation is funded by the Xunta de Galicia (Government of Galicia), through grants awarded by the Galician Institute for Economic Promotion, as part of the Innovapeme business aid program for its 2024 call.

File number: IN848D-2024-00000045-00

FOEXGA Program – Misión Carolina

This entity was beneficiary of the FOEXGA Program.
The main objective of this aid is to encourage the implementation of foreign promotion actions that generate competitive advantages. The intended result is the promotion of SMEs and their products and services, increasing the number of export-based companies.

Reacciona Program

This entity was a beneficiary of the call for grants for modular specialized advisory services provided to Galician companies by collaborating entities.
The main objective of this grant is to strengthen the sustainable growth and competitiveness of SMEs and create jobs there through productive investments.
The intended result is the launch of an SME services program that, through collaborating companies, allows SMEs to implement improvement projects in various areas related to their strategic development, professionalization, and innovation.

Investigo Program

Grant to finance the hiring of young job seekers to carry out research and innovation initiatives.
[TR349V]